FDA Approves Pancreatic Cancer Drug Treatment After It Was Shown to Double Patient Lifespans

Cancer News

Article from Good News Network curated by Editor in Chief George Lundberg, MD, who notes: 

The U.S. Food and Drug Administration (FDA) has approved the use of Lynparza (olaparib) for treating stage 4 pancreatic cancer. A clinical trial showed prolongation of life in many patients.

Go to full article published by Good News Network.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Back to Cancer Insights